Alnylam Pharmaceuticals (ALNY) Operating Expenses (2009 - 2026)

Alnylam Pharmaceuticals has reported Operating Expenses for 18 years, with the latest figure at $898.5 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 55.97% year-over-year to $898.5 million; the trailing twelve-month figure through Mar 2026 stood at $3.5 billion (up 43.49% YoY), and the FY2025 full-year result was $3.2 billion, up 32.46% from the prior year.
• Operating Expenses for Q1 2026 stood at $898.5 million, down from $965.3 million in the prior quarter.
• The five-year high for Operating Expenses was $965.3 million in Q4 2025, with the low at $360.0 million in Q1 2022.
• Historically, Operating Expenses has averaged $615.8 million across 5 years, with a median of $556.1 million in 2023.
• Annual changes were most pronounced in 2022 — Operating Expenses dropped 1.05% — and 2026, when it surged 55.97%.
• Alnylam Pharmaceuticals' Operating Expenses stood at $523.6 million in 2022, then grew by 6.2% to $556.1 million in 2023, then rose by 25.57% to $698.3 million in 2024, then jumped by 38.23% to $965.3 million in 2025, then decreased by 6.92% to $898.5 million in 2026.
• The last three Operating Expenses figures came in at $898.5 million (Q1 2026), $965.3 million (Q4 2025), and $881.0 million (Q3 2025), per Business Quant data.